5 clinical trials found.
-
A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer: A Hoosier Cancer Research Network Clinical Trial LUN 17-321
The purpose of the study is to determine the safety and efficacy of having Durvalumab with concurrent chemoradiation followed by surgery in patients with surgically ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A PHASE III DOUBLE-BLINDED MULTICENTER RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a combination ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase 2 Open-label Multicenter Study of an Immunotherapeutic Treatment DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Selected Advanced and Recurrent Solid Tumours.
In this study, we are trying to determine the safety and ability of an investigational product, called DPX Survivac, to help the immune system fight ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase 2 Randomized Double-blind Study of Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy vs Placebo with Pembrolizumab and Chemotherapy in Front-line Metastatic KEAP1/NRF2- mutated Nonsquamous Non-Small Cell Lung (NSCLC)
The purpose of the study is to determine the safety and efficacy of telaglenastat in combination with pembrolizumab plus chemotherapy compared with placebo in combination ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor
To evaluate the efficacy of pemigatinib in participants with locally advanced/metastatic or surgically unresectable solid tumor malignancy with an activating FGFR mutation or translocation.Phase
Interventional
TRIAL ROLE: Sub Investigator
